MTOR and type 2 diabetes mellitus: Furthermore, enhanced ALP function and decreased expression of AD-related proteins were observed in T2DM mice and HG-cultured HT22 cells after rapamycin treatment (Fig. 1G–I; Fig. 2B–D), suggesting that reduced TFEB phosphorylation via mTOR inhibition can activate ALP and attenuate AD-like pathology.